In light of our findings, rigorous screening for anti-HBc positive/HBsAg negative in this community should be implemented especially among the risky groups, such as those immunocompromised with HBV-HIV co-infection or HBV-HIV-TB triple infection, to mitigate the likely progression to end-stage liver diseases. The gene discussed is KRT88P; the disease is coinfection.